Daily Cosmetic Research Analysis
Analyzed 7 papers and selected 3 impactful papers.
Summary
Analyzed 7 papers and selected 3 impactful articles.
Selected Articles
1. Global post-COVID shifts in leading cosmetic procedures: A multiregional time-series analysis.
Interrupted time-series analysis of ISAPS global survey (2017–2024) shows a pronounced immediate post‑COVID surge in overall cosmetic procedural volumes with notable regional differences: nonsurgical fat reduction increased globally; abdominoplasty rose markedly in US and Latin America; Europe saw declines in liposuction, botox and peels.
Impact: Provides the largest recent multiregional quantitative evidence of how the pandemic reshaped demand for specific cosmetic procedures—important for workforce planning, supply-chain and public health surveillance in aesthetic medicine.
Clinical Implications: Clinicians and clinics should anticipate sustained higher volumes for certain procedures (e.g., nonsurgical fat reduction, abdominoplasty in some regions), adapt training and inventory, and monitor regional demand shifts to align services and safety capacity.
Key Findings
- Global immediate post‑COVID surge in cosmetic procedural volumes with sustained upward trend thereafter.
- Nonsurgical fat reduction increased significantly worldwide in the immediate post‑pandemic period.
- Regional heterogeneity: abdominoplasty increased in US and Latin America; blepharoplasty and rhinoplasty increased in Latin America; Europe saw declines in liposuction, botox injections and chemical peels.
Methodological Strengths
- Use of long-term (2017–2024) international ISAPS survey data enabling multiregional interrupted time-series analysis.
- Procedure-specific quantitative estimates with absolute change values (Δ) allowing comparison across regions.
Limitations
- Abstract does not state exact sample size or response rates from ISAPS survey; potential sampling or reporting biases across regions.
- Observational interrupted time-series cannot fully account for all confounders (e.g., changes in access, economic factors, telemedicine effects).
Future Directions: Follow-up studies should report respondent-level sample sizes, incorporate socioeconomic and access variables, and examine patient-level motivations and outcomes to contextualize procedural trends.
This study examines the immediate impact of the COVID-19 pandemic on aesthetic procedural rates, across the United States (US), Latin America, Europe, and Asia. Procedural counts from 2017 to 2024 were extracted from the International Society of Aesthetic Plastic Surgery's global survey. An interrupted time series analysis compared short-term procedural volume rates to pre-pandemic trends for leading cosmetic procedures. Globally, nonsurgical fat reductions increased significantly in the immediate post-pandemic period. In the US and Latin America, abdominoplasties increased (+Δ92,018; +Δ28,534), while blepharoplasties (+Δ14,218) and rhinoplasties (+Δ19,323) increased in Latin America only. Conversely, Europe experienced declines in surgical liposuction (-Δ6399), botox injections (-Δ38,033) and chemical peels (-Δ18,577). Despite regional variability, a sharp universal post-pandemic surge occurred, followed by a sustained upward trend in cumulative global procedural volumes.
2. See, Touch, Feel, and Express: Achieving Safe and Natural Outcomes With HA Fillers-An International Consensus.
An international multidisciplinary panel produced a consensus 'Natural Outcomes Framework' for HA fillers that prioritizes safety and defines naturalness across four domains: See, Touch, Feel, and Express. The framework emphasizes product (biomimetic design, rheology, low inflammatory potential), patient, and injector factors and provides a clinical workflow from pre‑treatment to follow‑up.
Impact: Provides a practical, safety‑centered framework and standardized language for defining and measuring 'natural' filler outcomes—fills an important gap in aesthetic practice and clinician-patient communication.
Clinical Implications: Clinicians can adopt the framework to standardize outcome goals, select biomimetic HA products with appropriate rheology and low inflammatory potential, individualize treatment, and implement the recommended workflow to reduce complications and improve patient satisfaction.
Key Findings
- Definition of natural outcomes across four domains: See (visual), Touch (tactile), Feel (experiential), Express (dynamic/functional).
- Safety is emphasized as foundational to natural outcomes; framework integrates product, patient, and injector factors.
- A practical clinical workflow is proposed to guide pre-treatment assessment, injection technique, and follow-up to achieve predictable, natural results.
Methodological Strengths
- Multidisciplinary international expert panel with literature review, survey input, and expert meeting contributing to consensus.
- Actionable framework translating conceptual definitions into a clinical workflow and product/technique recommendations.
Limitations
- Consensus statements represent expert opinion rather than high-level empirical evidence or randomized comparisons.
- Implementation feasibility and inter-rater reliability of proposed assessments (See/Touch/Feel/Express) require validation in prospective studies.
Future Directions: Prospective validation of the framework including standardized metrics, inter-rater reliability studies, and trials comparing outcomes using the framework versus standard practice are needed.
BACKGROUND: The concept of "natural outcomes" in filler treatments has been explored in clinical studies and literature, yet remains loosely defined, subjective, and lacks standardized assessment criteria. AIMS: To propose a multidimensional Natural Outcomes Framework to systematically define, assess, and communicate natural outcomes following hyaluronic acid (HA) filler treatment, facilitating attainment of desired results. METHODS: An international aesthetic multidisciplinary panel developed consensus statements and a practical framework for achieving safe and natural outcomes with HA fillers based on insights from a literature review, survey, and expert meeting. RESULTS: This expert consensus emphasizes safety as a foundational aspect of natural outcomes. The framework extends beyond visual outcomes ("See") to encompass tactile ("Touch"), experiential ("Feel") and expressive ("Express") dimensions of naturalness, which can be assessed by various methods. The panel identified three categories of factors affecting natural outcomes: product, patient, and injector factors. Treatment can be optimized by selecting HA fillers with biomimetic design, suitable rheological properties, and low inflammatory potential; ensuring knowledge and technical competency; individualizing treatment plans; and fostering effective communication. A practical clinical workflow was devised to guide the attainment and assessment of safe and natural outcomes from pre-treatment to follow-up. CONCLUSIONS: The Natural Outcomes Framework offers a structured approach to achieving safe and desired outcomes with HA fillers, aligned with this principle: "treat the patient, not the photograph." It promotes patient-practitioner alignment on treatment goals and use of appropriate products based on biomimetic design principles, contributing to the attainment of predictable and satisfying results with aesthetic HA filler treatments.
3. Recent advances in microneedle technology in transdermal drug delivery systems.
Narrative review of recent microneedle (MN) advances covering design, materials, fabrication, AI/3D‑printing-enabled optimization, and diverse applications including vaccination, biologics, sustained transdermal delivery and cosmetics; highlights translational challenges such as safety, scalability, regulatory pathways and dimensional/toxicity concerns.
Impact: Synthesizes technical and translational developments that position microneedles to enable new cosmetic delivery formats and broaden therapeutic transdermal options—important for both industry and clinical translational pipelines.
Clinical Implications: Though primarily translational, the review indicates imminent cosmetic applications (e.g., peptide delivery, sustained topical biologics) and highlights the need for safety testing, regulatory strategy, and clinician training prior to routine clinical adoption.
Key Findings
- Microneedles enable transdermal delivery of a wider range of molecules (vaccines, biologics, peptides) beyond traditional TDD limits by creating microchannels.
- Integration of computational modeling, AI, and 3D printing accelerates design optimization and customizability for cosmetic and therapeutic applications.
- Translational barriers remain: dimensional reproducibility, safety/toxicity, scalability, regulatory pathways and sustainability must be addressed for clinical rollout.
Methodological Strengths
- Comprehensive coverage of engineering, materials science, and regulatory considerations bridging bench-to-clinic perspectives.
- Highlights modern toolchains (AI, computational modeling, 3D printing) that materially influence design and scale-up.
Limitations
- Narrative review format may not systematically appraise all primary studies or provide quantitative synthesis.
- Practical clinical evidence for many cosmetic MN applications remains limited; safety and comparative effectiveness data are sparse.
Future Directions: Priorities include standardized preclinical safety testing, randomized/controlled clinical trials for cosmetic indications, regulatory pathway development, and scalable manufacturing methods informed by computational design.
INTRODUCTION: Transdermal drug delivery systems (TDDs) have abundant advantages over traditional drug administration routes (oral and parenteral), however the barrier function of the stratum corneum limits its application to compounds possessing the obligatory physicochemical characteristics. To overcome limitations of TDD, micro-sized needles can be used. Microneedles (MN), a noninvasive drug delivery system, can disrupt the skin's integrity, generating microchannels that facilitate the efficient infusion of drugs. AREAS COVERED: The review highlights recent advances in microneedle technology in transdermal drug delivery systems. The designing, (bio)materials, classification, fabrication, optimization, and characterization of microneedles are covered. The application of microneedles for vaccination, sustained transdermal delivery, biologics, targeted drug delivery, cosmetics, and advanced therapeutic applications are explored. The involvement computational modeling and AI-driven approaches, 3D printing, etc. is included. The critical challenges in microneedle development, e.g. dimensional concerns, safety, adequacy, toxicity, scalability, regulatory, and sustainability, are also covered. EXPERT OPINION: Developments MN technology have extended the potential of the transdermal drug delivery system, holding potential to transform areas like immunization, chronic disease treatment, pain management, and real-time biomonitoring. In the upcoming decade, drug delivery procedures are expected to prioritize people's ease and self-supervision, decreasing dependence on needles and hospitals; however, supervisory synchronization, maneuver calibration, and sustained novelty will be indispensable for MNs to develop as a standard of care.